I Holen

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
    Penny E Reid
    Academic Units of Clinical Oncology and Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Mol Cancer 8:49. 2009
  2. ncbi Evaluation of the current knowledge limitations in breast cancer research: a gap analysis
    Alastair Thompson
    Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Avenue, Dundee DD1 9SY, UK
    Breast Cancer Res 10:R26. 2008
  3. ncbi Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
    Penelope D Ottewell
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
    J Natl Cancer Inst 100:1167-78. 2008
  4. ncbi Role of osteoprotegerin (OPG) in cancer
    Ingunn Holen
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield S10 2RX, U K
    Clin Sci (Lond) 110:279-91. 2006
  5. ncbi Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Ingunn Holen
    Bone Oncology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 92:207-15. 2005
  6. ncbi Tumour macrophages as potential targets of bisphosphonates
    Thea L Rogers
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, South Yorkshire, S10 2RX, UK
    J Transl Med 9:177. 2011
  7. ncbi Anti-tumour activity of bisphosphonates in preclinical models of breast cancer
    Ingunn Holen
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK
    Breast Cancer Res 12:214. 2010
  8. ncbi Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological varia
    S S Cross
    Academic Unit of Pathology, School of Medicine and Biomedical Sciences, University of Sheffield, UK
    J Clin Pathol 59:716-20. 2006
  9. ncbi Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis
    H L Neville-Webbe
    Clinical Oncology, Division of Genomic Medicine, School of Medicine and Biological Sciences, University of Sheffield, UK Sheffield Bone Oncology Group, UK
    Breast Cancer Res Treat 86:269-79. 2004
  10. ncbi Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
    H L Neville-Webbe
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Br J Cancer 102:1010-7. 2010

Collaborators

Detail Information

Publications44

  1. ncbi Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
    Penny E Reid
    Academic Units of Clinical Oncology and Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Mol Cancer 8:49. 2009
    ..This study aims to elucidate the processes involved in the pro-angiogenic effects of OPG in vitro, and also how OPG levels may be regulated within the tumour microenvironment...
  2. ncbi Evaluation of the current knowledge limitations in breast cancer research: a gap analysis
    Alastair Thompson
    Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Avenue, Dundee DD1 9SY, UK
    Breast Cancer Res 10:R26. 2008
    ..A gap analysis was conducted to determine which areas of breast cancer research, if targeted by researchers and funding bodies, could produce the greatest impact on patients...
  3. ncbi Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
    Penelope D Ottewell
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
    J Natl Cancer Inst 100:1167-78. 2008
    ..We investigated the effects of clinically achievable doses of doxorubicin (Dox) and Zol, given alone, in sequence, and in combination, on the growth of established breast tumors in vivo...
  4. ncbi Role of osteoprotegerin (OPG) in cancer
    Ingunn Holen
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield S10 2RX, U K
    Clin Sci (Lond) 110:279-91. 2006
    ..This review provides an overview of the role of OPG in cancer, both in cancer-induced bone disease and in tumour growth and survival...
  5. ncbi Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Ingunn Holen
    Bone Oncology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 92:207-15. 2005
    ..To our knowledge these results are the first to demonstrate that OPG can act as an endocrine survival factor for breast cancer cells, as well as reporting the expression patterns of OPG in a large cohort of human breast tumours...
  6. ncbi Tumour macrophages as potential targets of bisphosphonates
    Thea L Rogers
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, South Yorkshire, S10 2RX, UK
    J Transl Med 9:177. 2011
    ....
  7. ncbi Anti-tumour activity of bisphosphonates in preclinical models of breast cancer
    Ingunn Holen
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK
    Breast Cancer Res 12:214. 2010
    ..Evidence for effects on different processes and cell types involved in cancer development and progression is discussed, and the main outstanding issues identified...
  8. ncbi Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological varia
    S S Cross
    Academic Unit of Pathology, School of Medicine and Biomedical Sciences, University of Sheffield, UK
    J Clin Pathol 59:716-20. 2006
    ..Their functions are linked by their interactions with osteoprotegerin (OPG)...
  9. ncbi Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis
    H L Neville-Webbe
    Clinical Oncology, Division of Genomic Medicine, School of Medicine and Biological Sciences, University of Sheffield, UK Sheffield Bone Oncology Group, UK
    Breast Cancer Res Treat 86:269-79. 2004
    ..Our data suggest that bone-derived OPG may increase survival of breast cancer cells that reach the bone microenvironment as part of the metastatic process...
  10. ncbi Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
    H L Neville-Webbe
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Br J Cancer 102:1010-7. 2010
    ..The potential biological interaction of these two drugs in breast cancer has not been assessed...
  11. ncbi Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone
    N A Cross
    Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK
    Prostate 68:1707-14. 2008
    ..We have tested this hypothesis using a xenograft model of early growth of prostate cancer in bone...
  12. ncbi Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro
    H L Neville-Webbe
    Cancer Research Centre, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK
    Tumour Biol 27:92-103. 2006
    ..Finally, we have found that the synergistic induction of apoptosis is via zoledronic acid-mediated inhibition of the mevalonate pathway...
  13. ncbi Combined therapies of bone disease with bisphosphonates
    S P Syddall
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK
    Curr Pharm Des 16:2988-97. 2010
    ....
  14. ncbi Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone
    Penelope D Ottewell
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
    Mol Cancer Ther 8:2821-32. 2009
    ..Our data are the first to show the specific molecular pathways by which sequential treatment with doxorubicin and zoledronic acid induce tumor cell apoptosis and inhibit proliferation in an in vivo model of breast tumor growth in bone...
  15. ncbi Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours
    C Van Poznak
    Academic Units of Clinical Oncology, Division of Genomic Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield S10 2RX, UK
    J Clin Pathol 59:56-63. 2006
    ..This specificity may provide a useful marker of functional differentiation in breast cancer; for example, TRAIL expression as a marker of myoepithelial differentiation...
  16. ncbi Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
    Ingunn Holen
    Bone Oncology Group, Divisions of Clinical Sciences and Genomic Medicine, Medical School, University of Sheffield, Sheffield, UK
    Cancer Res 62:1619-23. 2002
    ..These observations suggest that prostate cancer-derived OPG may be an important survival factor in hormone-resistant prostate cancer cells...
  17. ncbi Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo
    H K Brown
    Academic Unit of Clinical Oncology, Medical School, University of Sheffield, Sheffield, UK
    Clin Exp Metastasis 29:927-38. 2012
    ....
  18. ncbi Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
    Simon S Cross
    Academic Units of Clinical Oncology, Pathology and Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Int J Cancer 118:1901-8. 2006
    ..This is the first study to report the proangiogenic effects of OPG in vitro, as well as correlating expression of OPG by tumour endothelial cells with clinicopathological data in human tumours...
  19. ncbi Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?
    Maria Michailidou
    Academic Units of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    J Vasc Res 47:481-93. 2010
    ....
  20. ncbi From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies
    P D Ottewell
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 96:101-13. 2006
    ....
  21. ncbi Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis
    Rachel Nyambo
    Academic Unit Urology, Division of Clinical Sciences, Medical School, University of Sheffield, Sheffield, S10 2RX, UK
    J Bone Miner Res 19:1712-21. 2004
    ..These data suggest that at least part of the survival advantage gained by CaP cells in colonizing bone may be caused by the production of OPG by tumor-associated stromal cells...
  22. ncbi Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
    H K Brown
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK
    Curr Cancer Drug Targets 9:807-23. 2009
    ....
  23. ncbi Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy
    Rhys D Clyburn
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Cancer Chemother Pharmacol 65:969-78. 2010
    ..Here, we investigated whether apoptotic cell death is increased when zoledronic acid and doxorubicin are given in sequence or in combination in prostate cancer cells in vitro...
  24. ncbi Bisphosphonates as treatment of bone metastases
    Ingunn Holen
    Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, S10 2SJ, UK
    Curr Pharm Des 16:1262-71. 2010
    ..We also give an overview of the use of bisphosphonates in the treatment of breast cancer, including examples of key clinical trials. The potential side effects and future clinical applications of bisphosphonates will be outlined...
  25. ncbi Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates
    C Wilson
    Academic Unit of Clinical Oncology, Cancer Clinical Trials Centre, Weston Park Hospital, Sheffield, UK
    Cancer Treat Rev 38:877-89. 2012
    ....
  26. ncbi Expression and activity of ADAMTS-5 in synovium
    M N Vankemmelbeke
    Division of Genomic Medicine, University of Sheffield Medical School, Sheffield, UK
    Eur J Biochem 268:1259-68. 2001
    ..The possibility that synovium-derived ADAMTS-5 may play a role in cartilage aggrecan breakdown is discussed...
  27. ncbi Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
    Helen L Neville-Webbe
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom
    Int J Cancer 113:364-71. 2005
    ..These findings may have relevance for the clinical setting, particularly breast cancer patients receiving these drugs in the adjuvant setting...
  28. ncbi Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer
    Colby L Eaton
    Academic Urology Unit, University of Sheffield Medical School, Sheffield, United Kingdom
    Prostate 59:304-10. 2004
    ..In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated patients receiving androgen ablation...
  29. ncbi Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro
    Julia K L Woodward
    Academic Unit of Clinical Oncology, Genomic Medicine, Medical School, University of Sheffield, UK
    Anticancer Drugs 16:845-54. 2005
    ..For 10 microM zoledronic acid, pre- or post-doxorubicin also reduces invasion, but for this combination inhibition of cell growth may contribute to the reduction in invasion observed...
  30. ncbi Metastasis and bone loss: advancing treatment and prevention
    Robert E Coleman
    Yorkshire Cancer Research Professor of Medical Oncology, Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S102SJ, UK
    Cancer Treat Rev 36:615-20. 2010
    ....
  31. ncbi Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion
    Julia K L Woodward
    Academic Unit of Clinical Oncology, Division of Genomic Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Anticancer Drugs 16:11-9. 2005
    ..This review discusses the preclinical evidence for the potential use of BPs and cytotoxic drugs for inhibiting tumor cell invasion, a key process in cancer progression...
  32. ncbi Pathophysiological roles of osteoprotegerin (OPG)
    Penny Reid
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield S10 5RX, UK
    Eur J Cell Biol 88:1-17. 2009
    ..This review aims to provide an update on this area and assess the potential protective or detrimental role of OPG in both vascular pathologies and tumourigenesis...
  33. ncbi Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo
    Penelope D Ottewell
    School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Clin Cancer Res 14:4658-66. 2008
    ..We have therefore investigated the antitumor effects of clinically relevant doses of these drugs in a mouse model of breast cancer bone metastasis...
  34. ncbi The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers
    Elizabeth A Waterman
    Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
    Int J Cancer 121:1958-66. 2007
    ..We conclude that care should be exercised using this antibody for immunohistochemistry studies, without additional in situ hybridisation, or parallel use of other OPG-specific antibodies...
  35. ncbi Exploring the anti-tumour activity of bisphosphonates in early breast cancer
    M C Winter
    Academic Unit of Clinical Oncology, Section for Cancer, Cancer Research Centre, University of Sheffield, Weston Park Hospital, Sheffield S10 2SJ, UK
    Cancer Treat Rev 34:453-75. 2008
    ....
  36. ncbi Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
    N A Cross
    Academic Urology Unit, University of Sheffield Medical School, Sheffield, UK
    J Cell Biochem 104:1452-64. 2008
    ..These results highlight potential limitations of experiments designed to test contribution of factors affecting intrinsic apoptosis susceptibility using cloned tumour cell populations...
  37. ncbi Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells
    I Holen
    Division of Genomic Medicine, University of Sheffield Medical School, Sheffield, UK
    Br J Haematol 114:414-21. 2001
    ..These data indicate that a non-matrix-type metalloproteinase is responsible for syndecan-1 shedding from the surface of myeloma cells...
  38. ncbi The anti-tumour activity of bisphosphonates
    H L Neville-Webbe
    Department of Clinical Oncology, Cancer Research Centre, Sheffield, UK
    Cancer Treat Rev 28:305-19. 2002
    ..Ongoing research aims to assess this further, in addition to determining more precisely the role of adjuvant bisphosphonates in cancers such as breast and prostate cancer...
  39. ncbi The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer
    Julia K L Woodward
    Academic Unit of Clinical Oncology, D Floor, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
    Bone 41:912-27. 2007
    ..The results from trials involving protease inhibitors in clinical development will also be briefly discussed...
  40. ncbi Optimizing the yield and utility of circulating cell-free DNA from plasma and serum
    Xiaoyan Xue
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK
    Clin Chim Acta 404:100-4. 2009
    ..We therefore evaluated different aspects of laboratory protocols for the processing and purification of CFDNA in clinical studies...
  41. ncbi Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth
    Hannu Mönkkönen
    Department of Pharmaceutics, University of Kuopio, Kuopio, Finland
    Anticancer Drugs 19:391-9. 2008
    ..Additionally, the potency of clodronate to inhibit cancer cell growth corresponds to ATP analog formation...
  42. ncbi Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
    Daniele Santini
    Clinical Oncology, University Campus Bio Medico, 00155 Rome, Italy
    Oncol Rep 15:1351-7. 2006
    ..Future clinical trials should be designed to prospectively evaluate the prognostic role of reduction of betaCTX and VEGF in response to ZOL to predict clinical and skeletal outcome...
  43. ncbi Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Nat Clin Pract Oncol 3:325-38. 2006
    ..We briefly discuss identification of new molecular targets of bisphosphonates from genomic and proteomic analysis, and highlight the cellular consequences of drug-related enzyme inhibition...
  44. ncbi Zoledronic acid-induced IPP/ApppI production in vivo
    Hannu Mönkkönen
    Department of Pharmaceutics, University of Kuopio, Finland
    Life Sci 81:1066-70. 2007
    ..Importantly, this is the first report of in vivo production of ApppI, supporting the biological significance of this molecule...